Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study presented
“These positive preliminary efficacy and safety data underscore the promise of KB-0742 to treat patients with transcriptionally addicted tumors. The observed anti-tumor activity and absence of grade 3/4 neutropenia are particularly encouraging as we continue to enroll patients and explore a maximum tolerated dose,” said Jorge DiMartino, M.D., Ph.D., Chief Medical Officer and Executive Vice President, Clinical Development. “We look forward to advancing the study and reporting additional results, including data from the dose expansion portion of the study, mid next year.”
Share:
More News
“KEYTRUDA has helped transform the treatment of certain cancers, and we continue to pursue innovations that build on this breakthrough medicine to give patients and those who treat them better experiences,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “If approved,
“We are disappointed for ovarian cancer patients desperately lacking new treatment options. There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. We are still on track to
“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We deeply appreciate the patients and investigators who participated in the trial, and we look
“We are grateful for the ongoing guidance and support from the FDA and are very pleased that the agency is fully aligned on our plans related to the Phase 3 trial,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The Phase 2 OVATION 2 study data are
